Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Short-term Investments (2016 - 2025)

VYNE Therapeutics' Short-term Investments history spans 9 years, with the latest figure at $5.0 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 88.02% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $5.0 million, down 88.02%, while the annual FY2025 figure was $5.0 million, 88.02% down from the prior year.
  • Short-term Investments reached $5.0 million in Q4 2025 per VYNE's latest filing, down from $17.6 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $66.9 million in Q1 2024 to a low of $1.0 million in Q1 2021.
  • Average Short-term Investments over 4 years is $35.5 million, with a median of $41.6 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: crashed 95.68% in 2021, then tumbled 33.6% in 2024.
  • A 4-year view of Short-term Investments shows it stood at $1.0 million in 2021, then skyrocketed by 5998.64% to $62.6 million in 2023, then crashed by 33.6% to $41.6 million in 2024, then tumbled by 88.02% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Short-term Investments are $5.0 million (Q4 2025), $17.6 million (Q2 2025), and $22.1 million (Q1 2025).